

ASX ANNOUNCEMENT MARKET RELEASE

2 April 2024

ISSUE OF SHARES ON EXERCISE OF OPTIONS

Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company focused on commercialising its patented AI platform that detects key coronary artery disease imaging markers, advises that today the Company issued 55,000 ordinary shares on exercise of unlisted employee options.

An Appendix 2A will be lodged with ASX following this announcement.

Also attached is a cleansing notice issued in respect of the issue of shares.

This announcement was approved by the Board.

For further information please contact:

Investors

Danny Younis

+61 420 293 042

danny.younis@automicgroup.com.au

Media

Tristan Everett

+61 403 789 096

tristan.everett@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The Company has developed deep learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com

Salix® is a trademark of Artrya Limited

ASX ANNOUNCEMENT MARKET RELEASE

2 April 2024

SECONDARY TRADING NOTICE – NOTIFICATION PURSUANT TO PARAGRAPH 708A(5)(E) OF THE CORPORATIONS ACT 2001

Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company focused on commercialising its patented AI platform that detects key coronary artery disease imaging markers, provides this notice in accordance with section 708A(5)(e) of the *Corporations Act 2001* (Cth) (Corporations Act) in relation to an issue of 55,000 fully paid ordinary shares by Artrya on 2 April 2024 (Securities).

1. The Securities were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
2. As at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act.
3. As at the date of this notice, there is no excluded information (in accordance with the requirements of subsections 708A(7) and (8) of the Corporations Act).

Artrya Limited

Kevin Hart
Company Secretary

This announcement was approved by the Board.

For further information please contact:

Investors

Danny Younis
+61 420 293 042
danny.younis@automicgroup.com.au

Media

Tristan Everett
+61 403 789 096
tristan.everett@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The Company has developed deep learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com

Salix® is a trademark of Artrya Limited